Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label outcomes. Show all posts
Showing posts with label outcomes. Show all posts

Tuesday, June 22, 2021

Outcome after acute ischemic stroke is linked to sex-specific lesion patterns

So you have described something, but done nothing to help recover from these lesions. Useless. Predicting stroke severity doesn't help any survivor.

Outcome after acute ischemic stroke is linked to sex-specific lesion patterns

Abstract

Acute ischemic stroke affects men and women differently. In particular, women are often reported to experience higher acute stroke severity than men. We derived a low-dimensional representation of anatomical stroke lesions and designed a Bayesian hierarchical modeling framework tailored to estimate possible sex differences in lesion patterns linked to acute stroke severity (National Institute of Health Stroke Scale). This framework was developed in 555 patients (38% female). Findings were validated in an independent cohort (n = 503, 41% female). Here, we show brain lesions in regions subserving motor and language functions help explain stroke severity in both men and women, however more widespread lesion patterns are relevant in female patients. Higher stroke severity in women, but not men, is associated with left hemisphere lesions in the vicinity of the posterior circulation. Our results suggest there are sex-specific functional cerebral asymmetries that may be important for future investigations of sex-stratified approaches to management of acute ischemic stroke.

Introduction

Stroke affects >15 million people each year1. It is known to result in a substantial overall degree of long-term impairment across men and women2,3. However, numerous epidemiological studies indicate clinically relevant, sex-related differences in the characteristics of ischemic cerebrovascular disease4,5. For instance, due to a longer life expectancy, more women than men experience a stroke each year6. Expected demographical changes, i.e., an aging population, will widen this gap further: in the US, projections suggest that ~200,000 more women will be disabled after stroke than men by 20307.

Further sex differences relate to women more often presenting with non-classic stroke symptoms, such as fatigue or changes in mental status8,9, and having a higher risk of delays in hospital arrival10,11. Also, women feature a higher risk of cardioembolic stroke due to atrial fibrillation12, which may contribute to the often-observed higher acute ischemic stroke (AIS) severity in female patients13. This excess in stroke severity in women persists even after adjusting for their greater age at onset, comorbidities, and prestroke level of independence14,15. Importantly, women seem to experience more severe strokes despite comparable lesion sizes in men and women16. In fact, a similar observation of sex-specific lesion volume effects was noted in the case of aphasia, where women had a smaller lesion volume threshold to cause aphasia than men17.

Going beyond lesion volume, lesion-symptom mapping studies have enriched our understanding of anatomically unique lesion locations underlying specific symptoms post-stroke18,19,20. In the case of stroke severity, these analyses have determined widespread lesions in white matter, basal ganglia, pre- and postcentral gyri, opercular, insular, and inferior frontal regions to be most relevant for a higher stroke severity, especially if affecting the left hemisphere21. While these lesion-symptom studies have uncovered eloquent lesion locations with high spatial resolution, they have been systematically blind to any potential sex disparities. If considered at all, sex was treated as a nuisance variable and regressed out prior to the main analysis21. Thus, none of the recently employed analytical approaches in clinical neuroimaging allowed for a dedicated, explicit investigation of sex-specific lesion pattern effects in relation to continuous outcome scores.

In this work, we aim to design and conduct a lesion-symptom analysis capable of capturing male- and female-specific lesion patterns, underlying stroke severity in a statistically robust and spatially precise manner to address previous methodological constraints. For this purpose, we leverage neuroimaging data originating from two large, independent hospital-based cohorts gathering data of 555 (derivation) and 503 (validation) AIS patients in total. We tailor and deploy sex-aware hierarchical Bayesian models to simulate predictions of AIS severity and to elucidate the sex-specific effects of lesion patterns affecting similar brain regions in women and men. We seek to map the lesion constellations underpinning female-specific more severe strokes, potentially indicating sex-specific maps of functional deficits on the one hand and encouraging more sex-aware acute stroke treatment decisions on the other. Such a sex-informed acute stroke care has the potential to alleviate the burden of disease on an individual patient level, as well as broader and socioeconomically relevant levels.

Results

We here present a generative analysis of acute stroke severity, putting a particular focus on sex-specific lesion pattern effects. We successively combined (1) the automated low-dimensional embedding of high-dimensional DWI-derived lesion information via non-negative matrix factorization (NMF)22, and (2) probabilistic modeling, based on the latent NMF embedding, to simulate the prediction of acute stroke severity, as measured by the National Institute of Health Stroke Scale (NIHSS)23. We thus first determined pivotal, general lesion pattern effects across all patients and successively concentrated on similarities and differences between men and women (sex assessed by patients’ medical records). We interpreted explanatory relevances on the level of NMF-derived low-dimensional lesion representations, that we call lesion atoms, as well as the same relevances transformed back to the level of the anatomical gray matter brain regions and white matter tracts.

More at limk.

 

Physical activity after ischemic stroke and its association with adverse outcomes: A nationwide population-based cohort study

Are you sure you have the correct understanding of cause and effect? The stroke causes the lack of physical activity and thus adverse outcomes.

 Physical activity after ischemic stroke and its association with adverse outcomes: A nationwide population-based cohort study

Topics in Stroke Rehabilitation , Volume 28(3) , Pgs. 170-180.

NARIC Accession Number: J86310.  What's this?
ISSN: 1074-9357.
Author(s): Kang, Seong-Min ; Kim, Sun-Hyung ; Han, Kyung-Do ; Paik, Nam-Jong ; Kim, Won-Seok.
Publication Year: 2021.
Number of Pages: 11.

Abstract: 

Study identified the changes in physical activity (PA) level between before and after stroke and determined the relationship between PA and adverse outcomes. This observational, retrospective cohort study was performed using the Nationwide Health Insurance Service (NHIS) database in South Korea. Subjects between the ages of 20 to 80 years, who had a first-ever ischemic stroke from 2010 to 2013, were included. Subjects were divided into either the “sufficient” or “insufficient” subgroups, depending on the result of the self-reported PA questionnaire. Adverse outcomes, including all-cause mortality, stroke recurrence, and myocardial infarction (MI), were collected from a post-stroke health checkup to 2017. Of the 34,243 subjects with ischemic stroke, only 21.24 percent had sufficient PA level after stroke. Among those with insufficient PA level, only 17.34 percent improved their PA level after stroke. Subjects with sufficient PA level after stroke, regardless of their PA level prior to stroke, showed a lower risk of composite adverse outcomes. Subjects who went from insufficient to sufficient PA level showed a significantly lower risk of composite adverse outcomes. Achieving a sufficient PA level after ischemic stroke appears to significantly reduce major adverse events. Further effort is needed to promote the PA level after ischemic stroke.
Descriptor Terms: EXERCISE, INTERNATIONAL REHABILITATION, OUTCOMES, SECONDARY CONDITIONS, STROKE.


Can this document be ordered through NARIC's document delivery service*?: Y.

Citation: Kang, Seong-Min , Kim, Sun-Hyung , Han, Kyung-Do , Paik, Nam-Jong , Kim, Won-Seok. (2021). Physical activity after ischemic stroke and its association with adverse outcomes: A nationwide population-based cohort study.  Topics in Stroke Rehabilitation , 28(3), Pgs. 170-180. Retrieved 6/22/2021, from REHABDATA database.

Different strokes for different folks: Different outcomes are valued by different stakeholders

The only outcome measurement that is valid is what survivors want. 100% recoveryIf you don't understand that, GET THE HELL OUT OF STROKE! Quit trying to justify your failures.

 Different strokes for different folks: Different outcomes are valued by different stakeholders

In Proceedings of the 2020 Rehabilitation Engineering Society of North America (RESNA) Annual Conference

NARIC Accession Number: O22451.  What's this?
Author(s): Scherer, Marcia J. ; Smith, Roger O..
Publication Year: 2020.
Number of Pages: 4.

Abstract: 

This paper updates and extends an editorial written by the first author on “Technology Adoption, Acceptance, Satisfaction and Benefit: Integrating Various Assistive Technology Outcomes.” Additional stakeholders have been added as well as evidence-based outcomes measures applicable to each. It is critical for outcomes measurement developers, researchers, policy makers, people with disabilities, practitioners, funders, and service program administrators and managers to understand that each of their perspectives on outcomes is critical, but each of these unique perspectives is only one perspective of many. These many perspectives become even more important to consider when cultures, financial models, and service delivery programs, are unique as is the case across low- and middle-income countries where many of the outcomes systems were not originally developed. This paper was presented at the 2020 annual conference of Rehabilitative Engineering and Assistive Technology Society of North America (RESNA).
Descriptor Terms: ASSISTIVE TECHNOLOGY, INTERNATIONAL REHABILITATION, MEASUREMENTS, OUTCOMES, SERVICE UTILIZATION.


Can this document be ordered through NARIC's document delivery service*?: Y.
Get this Document: https://www.resna.org/sites/default/files/conference/2020/GAATO/146Scherer.html.

Citation: Scherer, Marcia J. , Smith, Roger O.. (2020). Different strokes for different folks: Different outcomes are valued by different stakeholders.  In Proceedings of the 2020 Rehabilitation Engineering Society of North America (RESNA) Annual Conference Retrieved 6/22/2021, from REHABDATA database.

Tuesday, June 15, 2021

Factors associated with time to independent walking recovery post-stroke

Useless. You give us nothing on how to change those factors to get to 100% recovery

  And your mentors and senior researchers were OK with such lousy outcomes?

Factors associated with time to independent walking recovery post-stroke

  1. Caitlin Kennedy1,
  2. Julie Bernhardt2,3,
  3. Leonid Churilov1,
  4. Janice M Collier2,
  5. Fiona Ellery2,
  6. Venesha Rethnam2,
  7. Lilian B Carvalho2,3,
  8. Geoffrey A Donnan4,5,
  9. Kathryn S Hayward2,3,6
  1. Correspondence to Dr Kathryn S Hayward, Melbourne School of Health Sciences, The University of Melbourne, Melbourne, VIC 3010, Australia; kate.hayward@unimelb.edu.au

Abstract

Background Past studies have inconsistently identified factors associated with independent walking post-stroke. We investigated the relationship between pre-stroke factors and factors collected acutely after stroke and number of days to walking 50 m unassisted using data from A Very Early Rehabilitation Trial (AVERT).

Methods The outcome was recovery of 50 m independent walking, tested from 24 hours to 3 months post-stroke. A set of a priori defined factors (participant demographics: age, sex, handedness; pre-stroke: hypertension, ischaemic heart disease, hypercholesterolaemia, diabetes mellitus, atrial fibrillation; stroke-related: stroke severity, stroke type, ischaemic stroke location, stroke hemisphere, thrombolysis) were investigated for association with independent walking using a cause-specific competing risk Cox proportional hazards model. Respective effect sizes are reported as cause-specific adjusted HR (caHR) adjusted for age, stroke severity and AVERT intervention.

Results A total of 2100 participants (median age 73 years, National Institutes of Health Stroke Scale 7, <1% missing data) with stroke were included. The median time to walking 50 m unassisted was 6 days (IQR 2–63) and 75% achieved independent walking by 3 months. Adjusted Cox regression indicated that slower return to independent walking was associated with older age (caHR 0.651, 95% CI 0.569 to 0.746), diabetes (caHR 0.836, 95% CI 0.740 to 0.945), severe stroke (caHR 0.094, 95% CI 0.072 to 0.122), haemorrhagic stroke (caHR 0.790, 95% CI 0.675 to 0.925) and right hemisphere stroke (caHR 0.796, 95% CI 0.714 to 0.887).

Conclusion Our analysis provides robust evidence for important factors associated with independent walking recovery. These findings highlight the need for tailored mobilisation programmes that target subgroups, in particular people with haemorrhagic and severe stroke.

Data availability statement

Data are available upon reasonable request to AVERT Executive Committee.

 

Monday, March 1, 2021

Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity

'More likely' IS NOT WHAT THE FUCK THIS RESEARCH IS SUPPOSED TO BE ABOUT!  Since you didn't measure 100% recovery this was useless.

Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity

JAMA Neurol. Published online March 1, 2021. doi:10.1001/jamaneurol.2021.0023


Key Points

Question  What is the association between telestroke capacity and care patterns and outcomes(You didn't measure 100% recovery?) for patients with acute ischemic stroke?

Findings  In this study including 153 272 patients treated for stroke, those who received care at hospitals with telestroke capacity had higher rates of reperfusion treatment and lower 30-day mortality compared with those treated at hospitals without telestroke. Increases in reperfusion treatment were largest in smaller hospitals, among rural residents, and among patients 85 years and older.

Meaning  Patients who present to hospitals with telestroke capacity were more likely to receive reperfusion treatment and have lower mortality.

Abstract

Importance  Telestroke is increasingly used in hospital emergency departments, but there has been limited research on its impact on treatment and outcomes.

Objective  To describe differences in care patterns and outcomes among patients with acute ischemic stroke who present to hospitals with and without telestroke capacity.

Design, Setting, and Participants  Patients with acute ischemic stroke who first presented to hospitals with telestroke capacity were matched with patients who presented to control hospitals without telestroke capacity. All traditional Medicare beneficiaries with a primary diagnosis of acute ischemic stroke (approximately 2.5 million) who presented to a hospital between January 2008 and June 2017 were considered. Matching was based on sociodemographic and clinical characteristics, hospital characteristics, and month and year of admission. Hospitals included short-term acute care and critical access hospitals in the US without local stroke expertise. In 643 hospitals with telestroke capacity, there were 76 636 patients with stroke who were matched 1:1 to patients at similar hospitals without telestroke capacity. Data were analyzed in July 2020.

Main Outcomes and Measures  Receipt of reperfusion treatment through thrombolysis with alteplase or thrombectomy, mortality at 30 days from admission, spending through 90 days from admission, and functional status as measured by days spent living in the community after discharge.

Results  In the final sample of 153 272 patients, 88 386 (57.7%) were female, and the mean (SD) age was 78.8 (10.4) years. Patients cared for at telestroke hospitals had higher rates of reperfusion treatment compared with those cared for at control hospitals (6.8% vs 6.0%; difference, 0.78 percentage points; 95% CI, 0.54-1.03; P < .001) and lower 30-day mortality (13.1% vs 13.6%; difference, 0.50 percentage points; 95% CI, 0.17-0.83, P = .003). There were no differences in days spent living in the community following discharge or in spending. Increases in reperfusion treatment were largest in the lowest-volume hospitals, among rural residents, and among patients 85 years and older.

Conclusions and Relevance  Patients with ischemic stroke treated at hospitals with telestroke capacity were more likely to receive reperfusion treatment and have lower 30-day mortality.

 

Tuesday, April 17, 2018

Improving outcomes for stroke survivors

Notice that there is absolutely nothing for your doctor to do for your recovery.
http://www.texarkanagazette.com/news/features/story/2018/apr/16/improving-outcomes-stroke-survivors/722175/
When Tiger Woods tied for fifth place at Bay Hill last March, it showed that his two-year-long recovery from knee and back surgeries was paying off. Now Tiger fans expect fewer strokes every time he plays.
That same principle of stroke recovery applies to the 7 million Americans who are stroke survivors. But far too many aren't getting back in their game because they've missed essential post-stroke recovery steps.
According to the American Heart Association, fewer than one in 100 stroke survivors is following all the recovery guidelines. They include: not smoking, getting regular physical activity, eating a healthy diet, plus achieving normal body mass index, blood pressure, glucose levels and total cholesterol. And we'd add two more: Learning how to manage stress and getting post-stroke rehab.
Rehab—as early as possible—boosts quality of life. It involves putting together a team of doctors, family, caregivers, physical and occupational therapists, nutritionists and others(They have no protocols to get you 100% recovered, you're screwed). To help figure this out, check out strokeassociation.org. Search for "Choosing the Right Stroke Rehab Facility."
To meet the dietary guidelines, adopt the MIND Diet (Mediterranean-DASH Diet Intervention for Neurodegenerative Delay) to protect the brain. To reduce the increased post-stroke risks of elevated glucose, BP and LDL cholesterol levels and ease depression and fatigue, boost your physical activity, along with medical management, if needed.
To live your healthiest, visit sharecare.com.
(c) 2018 Michael Roizen, M.D. and Mehmet Oz, M.D.

Wednesday, January 10, 2018

Multidisciplinary approach may improve outcomes in young women with ischemic stroke

Their lazy goal is to improve outcomes, NOT 100% recovery.  Lazy bastards.
https://www.news-medical.net/news/20171227/Multidisciplinary-approach-may-improve-outcomes-in-young-women-with-ischemic-stroke.aspx
A multidisciplinary approach aimed at providing emergency physicians with a foundation of knowledge regarding ischemic stroke in young women and addressing the unique challenges in the evaluation and diagnosis of ischemic stroke in young women may improve outcomes for patients served in the ED. That is the primary finding of a study to be published in the January 2018 issue of Academic Emergency Medicine (AEM), a journal of the Society for Academic Emergency Medicine (SAEM).
The lead author of the study is Bernard P. Chang, MD, PhD, assistant professor of medicine in the Department of Emergency Medicine, at Columbia University Medical Center, New York. Dr. Chang's research interests are in psychological and cardiovascular outcomes following acute medical events such as stroke and acute coronary syndrome.
The study, by Chang, et al, suggests that multiple opportunities exist for future research aimed at improving detection and treatment of young women with ischemic stroke. The authors propose that work aimed at creating and applying clinical decision rules, educational campaigns designed to educate young women and emergency medicine providers, and consideration of preventive strategies that might be applied in the emergency department may ultimately lead to interventions that can improve outcomes in young women with ischemic stroke.
The findings support the need to increase transparency and align incentives so that efficient, cost-effective, high-quality, definitive patient-centered care can be provided for all patients.
Andrew W. Asimos, MD, a professor in the Department of Emergency Medicine, Carolinas Medical Center and the Medical Director of the Carolinas Stroke Network, Carolinas HealthCare System commented:
"As with other thromboembolic disease processes, this review stresses the importance of recognizing non-atherosclerotic risk factors in premenopausal women that may predispose them to stroke. While future research in predictive modeling may lead to a decision rule that formally includes some or all of these risk factors, exploring for their existence in young women may help prompt diagnostic consideration for stroke, even with subtler clinical presentations. As machine learning and other artificial intelligence becomes increasingly integrated with the electronic medical record, I envision a future in which clinicians may be prompted to consider stroke in young woman, based on the presence of these risk factors."​

Wednesday, October 11, 2017

Transcranial direct current stimulation improves audioverbal memory in stroke patients

If it enhances outcomes write up a fucking stroke protocol.  A great stroke association president would make sure all stroke research with positive outcomes would be written up in a publicly available stroke protocol. Otherwise this research is just wasted. 
http://search.naric.com/research/rehab/redesign_record.cfm?search=2&type=all&criteria=J76784&phrase=no&rec=134604&article_source=Rehab&international=0&international_language=&international_location=
American Journal of Physical Medicine and Rehabilitation , Volume 96(8) , Pgs. 565-571.

NARIC Accession Number: J76784.  What's this?
ISSN: 0894-9115.
Author(s): Kazuta, Toshinari; Takeda, Kotaro; Osu, Rieko; Tanaka, Satoshi; Oishi, Ayakp; Kondo, Kunitsugu; Liu, Meigen.
Publication Year: 2017.
Number of Pages: 7.
Abstract: Study investigated whether anodal transcranial direct current stimulation over the left temporoparietal area improved audioverbal memory performance in stroke patients. Twelve stroke patients with audioverbal memory impairment participated in a single-masked, crossover, and sham-controlled experiment. The anodal or sham transcranial direct current stimulation was applied during the Rey Auditory Verbal Learning Test, which evaluates the ability to recall a list of 15 heard words over five trials. The number of correctly recalled words was compared between the anodal and sham conditions and the influence of transcranial direct current stimulation on serial position effect of the 15 words was also examined. The increase in the number of correctly recalled words from the first to the fifth trial was significantly greater in the anodal condition than in the sham condition. There was a significant difference between the anodal and sham conditions in the number of correctly recalled words within the first five words (primacy region) over the second to fifth trial trials, but not in the middle (next five words) or recency (last five words) regions. The results indicated that anodal transcranial direct current stimulation over the left temporoparietal area improved audioverbal memory performance and induced the primacy effect in stroke patients.
Descriptor Terms: BRAIN, ELECTRICAL STIMULATION, INTERVENTION, MEMORY, PHYSICAL MEDICINE, STROKE.


Can this document be ordered through NARIC's document delivery service*?: Y.

Citation: Kazuta, Toshinari, Takeda, Kotaro, Osu, Rieko, Tanaka, Satoshi, Oishi, Ayakp, Kondo, Kunitsugu, Liu, Meigen. (2017). Transcranial direct current stimulation improves audioverbal memory in stroke patients.  American Journal of Physical Medicine and Rehabilitation , 96(8), Pgs. 565-571. Retrieved 10/11/2017, from REHABDATA database.

Sunday, June 25, 2017

Optimal transcranial direct current stimulation polarity for enhancing motor recovery from severe post-stroke hemiparesis

If it enhances outcomes write up a fucking stroke protocol.  A great stroke association president would make sure all stroke research with positive outcomes would be written up in a publicly available stroke protocol. Otherwise this research is just wasted.
http://www.brainstimjrnl.com/article/S1935-861X(17)30738-6/abstract
Abstract #76
First page of article
Transcranial direct current stimulation (tDCS) has been shown to enhance outcomes of motor training for subjects with mild to moderate post-stroke motor deficit. To determine which tDCS configuration optimizes motor training in cases of severe post-stroke hemiparesis (≤ 19 out of 60, Fugl-Meyer Assessment (FMA) upper extremity motor score), this study randomized 26 subjects to 1 of 4 conditions: 1) “anodal” (anodal tDCS to the ipsilesional motor cortex); 2) “cathodal” (cathodal tDCS to the contralesional motor cortex); 3) “dual” (anodal tDCS to the ipsilesional motor cortex and cathodal tDCS to the contralesional motor cortex); or 4) “sham” tDCS.

To access this article, please choose from the options below

Wednesday, February 22, 2017

Identifying Strategies to Reduce Poor Outcomes in Women With Stroke

Well the simplest solution for reducing poor outcomes for every stroke survivor is to address these 5 causes of the neuronal cascade of death in the first week.  But I bet this paper doesn't discuss any of them.
http://circoutcomes.ahajournals.org/content/10/2/e003546?cpetoc=
Tracy E. Madsen, Lynda D. Lisabeth
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.


Introduction

Despite advances in care, stroke remains a leading cause of mortality and long-term disability around the world for both women and men.1 There are, however, notable sex differences in the epidemiology of stroke, including differences in incidence and mortality. Across the lifespan, women have a greater lifetime risk of stroke, a greater risk of death from stroke, and a higher risk of poor functional outcomes after stroke than men.2,3 A better understanding of the contributors to sex differences in stroke mortality could lead to the identification of strategies to improve stroke outcomes in women, as well as men. A study published in this issue by Phan et al4 included a meta-analysis using individual participant data from population-based studies to examine the contributors to sex differences in long-term mortality after stroke. The authors’ process of identifying contributors to the sex–mortality association in individual studies before combining data in a meta-analysis allowed them to clarify which factors contribute to higher stroke mortality in women and to identify potentially modifiable factors leading to poor stroke outcomes.
See Article by Phan et al
Their study is a meta-analysis of 13 studies of stroke incidence based on ideal population-based data sets; individual stroke incidence studies were conducted across Europe, Australia, South America, and the Caribbean between 1987 and 2013. Study authors examined all-cause mortality at 1 year after incident stroke in 13 studies (almost 17 000 patients) and all-cause mortality at 5 years after stroke in 8 studies (over 13 000 participants). Mortality rates were compared in …
View Full Text

Friday, February 3, 2017

A Critical Review of Alberta Stroke Program Early CT Score for Evaluation of Acute Stroke Imaging

Oh hell, instead of just predicting outcome tell us the outcome so you can fix the problems of those that don't have a good outcome.  DO SOMETHING USEFUL!

http://journal.frontiersin.org/article/10.3389/fneur.2016.00245/full?
  • Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Assessment of ischemic stroke lesions on computed tomography (CT) or MRI using the Alberta Stroke Program Early CT Score (ASPECTS) is widely used to guide acute stroke treatment. We aimed to review the current evidence on ASPECTS. Originally, the score was developed for standardized lesion assessment on non-contrast CT (NCCT). Early studies described ASPECTS as a predictor of functional outcome and symptomatic intracranial hemorrhage after iv-thrombolysis with a threshold of ≤7 suggested to identify patients at high risk. Following studies rather pointed toward a linear relationship between ASPECTS and functional outcome. ASPECTS has also been applied to assess perfusion CT and diffusion-weighted MRI (DWI). Cerebral blood volume ASPECTS proved to be the best predictor of outcome, outperforming NCCT-ASPECTS in some studies. For DWI-ASPECTS varying thresholds to identify patients at risk for poor outcome were reported. ASPECTS has been used for patient selection in three of the five groundbreaking trials proving efficacy of mechanical thrombectomy published in 2015. ASPECTS values predict functional outcome after thrombectomy. Moreover, treatment effect of thrombectomy appears to depend on ASPECTS values being smaller or not present in low ASPECTS, while patients with ASPECTS 5–10 do clearly benefit from mechanical thrombectomy. However, as patients with low ASPECTS values were excluded from recent trials data on this subgroup is limited. There are several limitations to ASPECTS addressed in a growing number of studies. The score is limited to the anterior circulation, the template is unequally weighed and correlation with lesion volume depends on lesion location. Overall ASPECTS is a useful and easily applicable tool for assessment of prognosis in acute stroke treatment and to help guide acute treatment decisions regardless whether MRI or CT is used. Patients with low ASPECTS values are unlikely to achieve good outcome. However, methodological constraints of ASPECTS have to be considered, and based on present data, a clear cutoff value to define “low ASPECTS values” cannot be given.

Introduction

The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is widely used in clinical practice to assess the extent of early ischemic changes on brain imaging for acute stroke treatment. ASPECTS has been applied to various imaging modalities in acute stroke imaging since its introduction in 2000. ASPECTS is a 10-point scoring system with anatomical regions distributed over the MCA territory (1).
It was designed as a robust imaging measure to predict outcome in intravenous thrombolysis. ASPECTS has drawn a lot of attention due to its use for patient exclusion in the 2015 trials demonstrating efficacy of mechanical thrombectomy (24).
Due to high efficacy, we will see an increase of mechanical thrombectomy over the course of the next years and with it probably an increasing use of ASPECTS in routine clinical practice, as patient stratification is key in this time-dependent treatment. There are also a rapidly growing number of scientific studies using ASPECTS in stroke research or addressing methodological questions concerning ASPECTS (please see Figure 1 for an overview of the number of studies published per year over the last 10 years). This article aims to summarize the current evidence on ASPECTS in a topical and selective review and to explain its applications in clinical practice and trials.

Monday, August 8, 2016

Bad pharma and the canary in the coalmine for problems in modern medicine

Our great stroke association should be following up every stroke trial and making sure all results are published. But that won't occur because YOU are expected to do the followup, your stroke association is doing nothing for survivors. He doesn't even knock statins for the real issue in atherosclerosis, that cholesterol is not the problem, inflammation is. With no inflammation, circulating cholesterol is not a problem.
https://cosmosmagazine.com/society/bad-pharma-and-the-canary-in-the-coalmine-for-problems-in-modern-medicine
Ben Goldacre is on the phone from London and he’s getting exercised about statins. “Statins are the canary in the cage for problems in modern medicine,” he says.
They are also the subjects of his next book – yet to be completed – and were addressed at some length in his last one, Bad Pharma (2012).
His continued focus is not surprising. For a host of reasons, research into statins and the prescribing patterns that research catalyses pretty much epitomise his concerns about medical academia.
They are concerns that, since he qualified as a medical doctor in 2000 after studies in Oxford, Milan and Los Angeles, have seen him move from GP, to author, to researcher, to, now, medical activist.
Goldacre, UK-born to Australian parents, fronts two long-term campaigns designed to bring about root and branch reform of the ways clinical trials are conducted and reported.
The first, AllTrials, has been running since 2013. It seeks to ensure that every trial is both registered with an appropriate authority and then published, regardless of result. At present, perhaps as much as 50% of trial write-ups never see the light of day.
The second campaign, CompareTrials (CT), kicked off late last year and aims to enforce procedural transparency in trials. At issue is the matter of switched priorities: trials that start by researching one outcome, but then change to another before the exercise is concluded.
Earlier this year, the CT team checked every trial published between October 2015 and January 2016 in five major publications, including the British Medical Journal and the Annals of Internal Medicine.
The results reported were compared to the outcomes specified when the trials were initially registered, or the founding protocols published. Out of 67, only nine did what they set out to do. In the rest, 354 stated outcomes were not completed, and 357 new ones were added.
Goldacre happily admits that CT is a “preposterously nerdy venture”. That said, however, it doesn’t diminish its importance.
“There’s a real problem in the way that clinical trials report their results. You can measure the outcome of your trial in hundreds of different ways,” he said.
Goldacre’s Bad Pharma comprises a detailed and depressing catalogue of the many ways in which researchers recalibrate their initial intentions and generally fiddle with the data.
He poses the hypothetical example a drug aimed at improving cardiovascular health. How baseline and improved health are assessed are matters of great complexity. Blood tests can measure perhaps 20 applicable lines of evidence, each set against potentially hundreds of cut-off points. Symptom questionnaires can be measured against a plethora of ratings scales. Hospital admissions can be recorded by treatment, code, doctors’ notes or length of stay. Patients can be monitored over days, weeks, years, decades.
“So you potentially have thousands and thousands of ways of measuring something like cardiovascular health,” he says, “And because there are so many ways of measuring it, that means the results are really vulnerable to cherry-picking.
“That’s why traditionally we ask people at the beginning of a clinical trial to specify exactly what they are going to measure as the success criteria, and exactly how they are going to measure it.”
Tradition, obligation, and principle, however, are not unbreakable bonds (as any subscriber to Retraction Watch can testify). Much of Goldacre’s Bad Pharma comprises a detailed and depressing catalogue of the many ways in which researchers – sometimes at the behest of the pharmaceutical companies sponsoring the work – recalibrate their initial intentions and generally fiddle with the data.
Sometimes this is merely a matter of spin – such as expressing a benefit as a relative rather than absolute risk reduction – but sometimes it is much more organic.
Outcome priorities are changed; negative results are omitted; trials are foreshortened or extended to better massage the data. In the book, Goldacre terms these tactics “a quiet and diffuse scandal”.
Perhaps this would not matter quite so much if it weren’t for the fact that published trial results feed into pharmaceutical marketing and doctor prescribing choices.
In Bad Pharma, Goldacre relates a trial featuring a new painkiller, celecoxib, that was tested against two other pills to assess side-effect gastrointestinal complications. The published study showed clearly that over a six-month period the new drug was way better than the old ones, leading many GPs to preference it in prescribing.
But it eventually came to light that the original intention of the trial was to test the three pills for a 12-month period – over which celecoxib performed no better than its rivals.
At the other end of scale, in the late 1990s pharmaceutical company GSK investigated anecdotal reports of deaths associated with its asthma inhaler drug Salmeterol. It set up a large clinical trial, with participants monitored intensively for 28 weeks.
It then asked participating doctors to keep an eye out for adverse events for another six months – but did not actively search for cases.
Not surprisingly, the period of intensive monitoring revealed a higher number of negative outcomes (measured against a placebo) than the follow-up period when no one was looking too hard. Changing its initial trial protocol, GSK reported the figure for the two periods combined, thus reducing the apparent severity of the problem.
Which brings us back to statins, the most commonly prescribed medication in the developed world, and Goldacre’s canaries.
In Bad Pharma, he points out that the two most popular prescribed statins, atorvastatin and simvastatin, both work well, but no one has ever tested them against each other to determine which one works better. This is an important point, because if one works only slightly better than the other it’s still a result that could convert into the prevention of thousands of strokes and heart attacks every year.
In the absence of this data, prescribing, Goldacre points out, is effectively a random act. But attempts to formally constitute that randomness as a countrywide trial in England met with a farcical level of bureaucratic complication. That makes statins “one of the most fascinating problems in medicine right now”.
“Over 100 million people take a statin every morning and yet there are huge gaps, firstly in our knowledge about which is best, and gaps in our knowledge about side effects,” he says.
“But also, we have failed, so badly, to communicate the modest benefits of these treatments to the public that there is huge widespread panic and anxiety among not just patients but also doctors, in many cases, about what the benefits of these treatments are.
“If we can’t get this stuff right for [statins] the single most commonly prescribed class of drug in the whole of the developed world – a tablet that is taken every day by 100 million people – then that’s a real window into our failures to do appropriate clinical trials throughout the whole of medicine.”
It’s a subject to which he will no doubt return, not only in his forthcoming book, but also in his upcoming speaking tour of Australian capital cities, kicking off in Brisbane on 22 September.
Dates and tickets can be found at www.thinkinc.org.au/events/ben-goldacre